TV News LIES

Tuesday, Feb 21st

Last update05:20:13 AM GMT

You are here News Health Study outcome won't sway company on eye drug

Study outcome won't sway company on eye drug

E-mail Print PDF

What does a company do when there's anecdotal evidence that two of its drugs are equally effective in treating a leading cause of blindness in the elderly, one costing patients $60 per treatment and the other $2,000?

In the case of Genentech Inc., nothing.

The company declined to seek federal approval for the cheaper drug, Avastin, to treat the wet form of age-related macular degeneration. Nor would it help finance _ or cooperate with _ a National Eye Institute study comparing the effectiveness and safety of Avastin, a cancer drug, and the more expensive eye drug, Lucentis.

More...


Most Recent Related Stories...


Bill Gates Warns That A Devastating Pandemic Is Right Around The Corner

Bill GatesA pandemic is one of the world’s top three threats, and if not prepared for, could...

Brain Scans Detect Signs of Autism in High-Risk Babies Before Age 1

autism in children under one dtected with brain scansIt may be possible to detect autism in babies before their first birthdays, a much earlier...

Court Strikes Down Florida Law Barring Doctors From Discussing Guns With Patients

Court strikes down gun discussion restriction for doctorsA federal appeals court says doctors in Florida must be allowed to discuss guns with their...

This drug just got the FDA's OK -- and an $89K price tag

FDA okays drug with $89,000K price tagA drug sold for years overseas to treat a rare form of muscular dystrophy was OKed...
 
America's # 1 Enemy
Tee Shirt
& Help Support TvNewsLIES.org!
TVNL Tee Shirt
 
TVNL TOTE BAG
Conserve our Planet
& Help Support TvNewsLIES.org!
 
Get your 9/11 & Media
Deception Dollars
& Help Support TvNewsLIES.org!
 
The Loaded Deck
The First & the Best!
The Media & Bush Admin Exposed!